Develops small-molecule medicines for epilepsies, psychoses and schizophrenia for people with neurological and psychiatric conditions.
10-K for FY2025, filed Mar 18, 2026
License partners pay for drug rights through fees and royalties; Ovid has also received one-time upfront payments, and license fees are tied to the license start and delivery of licensed material.
10-K for FY2025, filed Mar 18, 2026
$7.3M
10-K for FY2025, filed Mar 18, 2026
$7.3M ↗Takeda and Ligand are counterparties to Ovid's royalty and licensing arrangements; Ovid may work with third parties to commercialize candidates in markets where doing so is less capital efficient.
No. It lost $17.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$20.8MView ↗
8-K, filed Jul 8, 2026
On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer…View ↗
Shrinking. Revenue fell 97% in 4 years, from $208.4M in FY2021 to $7.3M in FY2025, about 57% a year.
Broader treatment targets
The older report centers on rare epilepsies and seizure-related neurological disorders; the latest report also targets psychosis associated with Parkinson's disease and Lewy body dementia, schizophrenia and mood disorders.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 18, 2026Ovid is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare…View ↗
Pipeline modalities
The older report includes genetic therapies, including antisense oligonucleotides, in the pipeline; the latest report describes the pipeline as consisting of small-molecule programs.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 18, 2026We cultivate a pipeline that utilizes a range of potential first-in-class or potential best-in-class MoAs to intercept and mitigate the…View ↗
Small molecule compounds. Ovid’s pipeline consists of small molecule programs that can potentially be delivered orally, by subcutaneous or…View ↗
Competes with UCB, Jazz Pharmaceuticals, SK Biopharmaceuticals, Harmony Biosciences, Xenon Pharmaceuticals, Acadia Pharmaceuticals, and Axonis Therapeutics
10-K for FY2025, filed Mar 18, 2026The fields of epilepsy, including FOS and DEEs such as TSC and IS, and psychiatric medicines are highly fragmented. There is no one direct…View ↗
Loading...